



Figure S1. The COVIDOSE algorithm for inpatient administration of low-dose tocilizumab to patients with moderate or severe COVID-19. Eligible COVIDOSE patients receive IL-6 axis-suppressing therapy. Patients have baseline clinical and laboratory-based risk stratification, and then receive an initial dose of tocilizumab. Usual clinical care continues for 24 hours after the initial tocilizumab dose, at which point repeat biochemical assessment is performed. If evidence of clinical decline and evidence of insufficient IL-6 axis suppression, COVIDOSE patients receive an additional dose of tocilizumab. COVID-19, novel coronavirus disease 2019; FiO₂, fraction of inspired O₂; IL-6, interleukin 6.